2026 Joint Annual Meeting of ACACR and USCACA

1:30 – 7:30 pm, Saturday, April 18, 2026

MET Lower Auditorium
T. Denny Sanford Medical Education and Telemedicine Center
University of California San Diego
9500 Gilman Dr, La Jolla

Organized by

Association of Chinese Americans in Cancer Research

www.acacr.org

United States Chinese Anti-Cancer Association

www.uscaca.org

Sponsored by

Massachusetts Biological Instruments Co.(MBI), Boston, MA
Metware Biotechnology Inc (MetwareBio), Woburn, MA
MedChemExpress (MCE), Monmouth Junction, NJ
RayBiotech, Peachtree Corners, GA
TargetMol, Wellesley Hills, MA
KYINNO Biotechnology, Woburn, MA
RWD Life Science Co., Ltd., Sugar Land, TX

Directions:

a). From San Diego downtown, take Interstate 5 North, exit at La Jolla Village Drive, turn left to the west, and then turn right into Gilman Drive, park at South Parking Structure (pay the visitor's parking fee).

b). Take Trolley train (15 min walk from Convention Center to the train station) to UCSD campus station.

c). Take Uber or Lyft to Denny Sanford Medical Education and Telemedicine Center.



Program

1:30 – 2:00 pm, Registration/check-in/vendor table setup

2:00 – 2:10 Welcome messages by Dr. Boyi Gan (ACACR President, MD Anderson Cancer Center) and Dr. Shi-Yong Sun (USCACA President, Emory University)

2:10 – 2:15 Announcement of 2025 Winners of Tony Hunter Award in Cancer Research by Award Committee Chair, Dr. Boyi Gan, ACACR President, MD Anderson Cancer Center

2:15 – 3:00 Keynote Speech (virtual): Dr. **Zhijian "James" Chen**, UT Southwestern Medical Center, Tony Hunter Award Lecture (Senior Investigator Awardee), introduced by Dr. Boyi Gan

Title: TBD

3:00 – 3:25 Dr. **Jun Wang**, New York University, Tony Hunter Award Lecture (Junior Investigator Awardee), introduced by Dr. Wei Xu. Award presentation by Dr. Tony Hunter.

Title: Probing novel immune feedback modulators for next-generation immunotherapies

3:25 – 3:35 AACR representative brief speech: Dr. **William Pao**, (Member of AACR Board of Directors, and Chair, the AACR Asian/AANHPI Task Force)

3:35 – 4:15 USCACA Award Session, Dr. Shi-Yong Sun, Emory University

USCACA Outstanding Young Chinese Scholar Awards Announcement and Presentations (Dr. Xuefeng Liu, The Ohio State University)

Brief presentation by Dr. Jinsong Liu, MD Anderson Cancer Center

4:15 – 4:35 Coffee break (Group Photo)

4:35 – 5:00 Business meeting of the two societies, chaired by Boyi Gan, ACACR President

1. Update on ACACR Publication (*Genes & Disease*): Dr. Zhenghe Wang, Case Western Reserve University and Dr. Tong-Chuan He, University of Chicago
2. ACACR Annual Finance Report: Dr. Wenwei Hu, ACACR Treasurer (2026-2028), Rutgers Cancer Institute

5 – 5:10 Speech by Dr. Gen-Sheng Feng, the past ACACR President

5:10 – 5:40 Sponsor presentations, chaired by ACACR General Secretary, Dr. Erxi Wu, Baylor College of Medicine

Gold Sponsors (3 min each):

Metware Biotechnology Inc (MetwareBio), Woburn, MA

MedChemExpress (MCE), Mommouth Junction, NJ

RayBiotech, Peachtree Corners, GA

TargetMol, Wellesley Hills, MA

KYINNO Biotechnology, Woburn, MA

Massachusetts Biological Instruments Co.(MBI), Boston, MA

RWD Life Science Co., Ltd., Sugar Land, TX

5:40 – 5:45 Concluding remarks, Dr. Wei Xu, ACACR President-elect, University of Wisconsin-Madison

5:45 – 7:30 Networking/Buffet Dinner

ACACR/USCACA 2026 Joint Annual Meeting Organizing Committee

Boyi Gan	The University of Texas MD Anderson Cancer Center
Wei Xu	University of Wisconsin-Madison
Shi-Yuan Cheng	Northwestern University
Xuefeng Liu	Ohio State University
Shi-Yong Sun	Emory University
Erxi Wu	Baylor College of Medicine
Lanjing Zhang	Rutgers University
Lin Zhang	University of Southern California
Jing Yang	University of California San Diego
Emily Wang	University of California San Diego

Association of Chinese Americans in Cancer Research (ACACR)

Tony Hunter Award in Cancer Research

Nomination Period: November 20 - December 20, 2025
Submission Deadline for Candidates: December 20, 2025
Review and Decision by Committee: January 1- January 11, 2026

Tony Hunter Award in Cancer Research was established in 2024 to recognize scientists of Chinese descent who have made fundamental or groundbreaking contributions to cancer research that exhibit significant or long-lasting impact on advancing our knowledge in basic and/or translational cancer research.

This award is named in honor of Dr. Tony Hunter, a world-renowned scientist who made seminal contributions to biomedical science in the discovery of the roles of protein tyrosine phosphorylation in cellular signaling critical in normal and pathological processes.

This award will be presented to one junior investigator and one senior investigator once a year at the annual ACACR meeting. Each awardee will give a presentation on the award-recognized research work when accepting the award.

Previous awardees:

Lieping Chen (2024 Senior Investigator Awardee)
Peiwen Chen (2024 Junior Investigator Awardee)
Chuan He (2025 Senior Investigator Awardee)
Liling Wan (2025 Junior Investigator Awardee)

Administration:

1. The Award Committee is composed of a total of 11 members selected by the ACACR Executive Committee; thus, we will execute on the two-third majority rule in committee voting.
2. The Award Committee shall be the body responsible for the solicitation of nomination, evaluation, and the selection of final candidate(s), based on the two-third majority rule.
3. The ACACR Executive Committee shall be the final awarding body in deciding the award to the nominee(s), based on the two-third majority rule.
4. The Chair of the Award Committee or his/her designate, on behalf of the ACACR Executive Committee, shall inform the selected recipient of this award.
5. The Award recipient will receive an award recognition plaque and an honorarium of $1,000 US dollars. The ACACR Executive Committee will be responsible for fundraising to support the two awards annually.

Eligibility:

1. Tony Hunter Award in Cancer Research (Junior Investigator)
   This category is open to candidates who are presently in a tenure-track assistant professor role or an equivalent position at a US research university or institute within his/her initial six-year appointment.
2. Tony Hunter Award in Cancer Research (Senior Investigator):
   Eligible candidates for this category are those holding a tenured full professor or an equivalent position at a US research university or institute. Additionally, exceptional mid-career candidates who currently hold a tenured associate professor position may also be considered.
3. The recipients must be members of ACACR at the time of accepting the award.

Nomination Process:

1. A qualified candidate can be nominated by the signatures of a minimum of three members of good standing, former recipients of this award, or any member of the Award Committee.
2. The nominated candidate shall provide the Award Committee a comprehensive curriculum vitae and a brief description of the major contributions or achievements in cancer research.
3. The Award Committee, on behalf of the ACACR Executive Committee, shall seek additional evaluation of the qualifications of the nominee, in the forms of recommendation letters and/or evaluation critiques.

Award Committee:

Chair:	Boyi Gan	The University of Texas MD Anderson Cancer Center
Members:	Wei Xu	University of Wisconsin-Madison
	Shi-Yuan Cheng	Northwestern University
	Xiaoqi Liu	University of Kentucky
	Wenwei Hu	Rutgers Cancer Institute of New Jersey
	Zhenkun Lou	Mayo Clinic
	Erxi Wu	Baylor College of Medicine
	Jing Yang	University of California San Diego
	Lanjing Zhang	Rutgers University
	Lin Zhang	University of Southern California
	Qing Zhang	University of Texas Southwestern Medical Center

2026 Tony Hunter Award Winner
(Senior Investigator Awardee)



Zhijian 'James' Chen was born in 1966 in Fujian Province in China. He received his B.S. degree in Biology in 1985 from Fujian Normal University and his Ph.D. degree in Biochemistry in 1991 from the State University of New York at Buffalo. After his postdoctoral training at the Salk Institute, Chen joined Baxter Healthcare in 1992 as a Research Scientist to work on Cancer Immunotherapy. In 1994, Chen became a Senior Scientist at ProScript Inc, a start-up biotechnology company where he helped discover the proteasome inhibitor VELCADE, a medicine used for the treatment of multiple myeloma and mantle cell lymphoma. In 1997, Chen joined the University of Texas Southwestern Medical Center (UT Southwestern) as an Assistant Professor and rose through the rank to become a Professor in 2005. Since 2005, Chen has been an Investigator of Howard Hughes Medical Institute. He is also George L. MacGregor Distinguished Chair in Biomedical Science and Director of Inflammation Research Center at UT Southwestern.

Chen has made a series of discoveries that transformed our understanding of cell signaling and innate immunity. Shortly after joining UT Southwestern in 1997, Chen discovered the regulatory role of ubiquitination in protein kinase activation in the NF-kB and MAP kinase pathways. In 2005, he discovered the Mitochondrial Antiviral Signaling (MAVS) protein that reveals a new role of mitochondria in immunity. He has since systemically dissected the MAVS pathway of RNA sensing, revealing prion-like polymerization of MAVS as a new signal transduction and amplification mechanism in antiviral and inflammatory responses. In 2012, Chen discovered cyclic GMP-AMP synthase (cGAS) as a cytosolic DNA sensor that triggers an innate immune response. In the same year, he discovered the cGAS product cyclic GMP-AMP (cGAMP) as the first metazoan cyclic dinucleotide that functions as a second messenger in innate immunity. These discoveries have led to intense efforts in the pharmaceutical industry in developing effective therapies against cancer and autoimmune diseases.

For his work, Chen has received numerous honors including the National Academy of Science Award in Molecular Biology (2012), American Society of Biochemistry and Molecular Biology (ASBMB) Merck Award (2015), Lurie Prize in Biomedical Sciences from the Foundation of NIH (2018), Breakthrough Prize in Life Sciences (2019), Switzer Prize (2019), William B. Coley Award for Distinguished Research in Basic and Tumor Immunology (2020), Louisa Gross Horwitz Prize (2023), Albert Lasker Award for Basic Medical Research (2024), Paul Ehrlich and Ludwig Darmstaedter Prize (2025), Elaine Redding Brinster Prize (2026) and Japan Prize in Life Sciences (2026). Chen is a member

of the National Academy of Sciences and the National Academy of Medicine, and a Fellow of the Royal Society.

2026 Tony Hunter Award Winner
(Junior Investigator Awardee)

Dr. Jun Wang is an Assistant Professor of Pathology at NYU Grossman School of Medicine. He earned a B.S. in Bioengineering from Nanjing Tech University, followed by a Ph.D. in Molecular Immunology from the Chinese Academy of Sciences, where he investigated the mechanisms underlying liver toxicity associated with anti-4-1BB immunotherapy. He subsequently completed postdoctoral training in cancer immunotherapy at Johns Hopkins University and Yale University.

Dr. Wang has over two decades of experience in immunotherapy, with a focus on immune checkpoint biology, the discovery of novel immune receptor–ligand pathways, and their translation into therapies for cancer and autoimmune diseases. He is among the first to characterize multiple immune regulatory mechanisms, including FGL1/LAG-3, FGL1/TACI, Siglec-15, MHC-I membrane inhibitory pathways, SARS-CoV-2 myeloid receptors, LAG-3–based bispecific T-cell silencers, and myeloid immune feedback modulators, establishing new paradigms for immune regulation and therapeutic intervention.

Dr. Wang is the founder and scientific advisor of Remunix Inc. and Feedback Tx, a founding scientist of NextCure Inc. (NASDAQ: NXTC), scientific co-founder of Rootpath Genomics, and co-founder of non-profit organization BioSpark Group. He also serves as a scientific advisory board member/advisor to multiple biotechnology companies, including Remunix, Henlius, Hanmi, LAV, and Regeneron. His contributions have been recognized with several honors, including the V Scholar Award, the Melanoma Research Alliance Young Investigator Award, and the Mark Foundation ASPIRE Award.

Meeting Organizing and Award Selection Committees



Boyi Gan, Ph.D., ACACR President. Dr. Gan holds the N.G. and Hellen T. Hawkins Distinguished Professor for Cancer Research and is the Director of Radiation and Cancer Metabolism Research Program at MD Anderson Cancer Center. Dr. Gan received his B.S. from Fudan University in China. In 2006, he obtained Ph.D. from Cornell University. He then conducted his postdoc training with Dr. Ron DePinho at Dana-Farber Cancer Institute, Harvard Medical School. In 2011, he joined the MD Anderson Cancer Center as a tenure track Assistant Professor. His research has been at the interface between cancer metabolism and cell death, with a focus on ferroptosis and disulfidptosis. His research on ferroptosis has provided critical insights into its role in cancer and potential therapeutic targeting. Dr. Gan elucidated ferroptosis as a crucial tumor suppression mechanism and identified mitochondria-localized ferroptosis defense mechanisms, underscoring the importance of compartmentalization in ferroptosis regulation. Dr. Gan discovered that radiotherapy induces ferroptosis, laying the foundation for novel combination treatment strategies to combat radioresistance in cancer. Notably, Dr. Gan discovered disulfidptosis, a novel form of cell death induced by disulfide stress, which has opened new avenues in cell death research. Dr. Gan has served as the PI of multiple extramural grants, including several active R01s and a U54 grant from National Institute of Health (NIH), and has published more than 140 papers, including last-author publications in *Nature*, *Cancer Cell*, *Nature Cell Biology*, and *Cancer Discovery*. He is the recipient of many awards, including Kimmel Scholar Award, Ellison Medical Foundation New Scholar Award, and The Dallas/Fort Worth Living Legend Faculty Achievement Award in Basic Research. He was an elected fellow of American Association for the Advancement of Science (AAAS) in 2023.

Shi-Yong Sun, Ph.D., USCACA President. Dr. Sun has been a tenured full Professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine and Winship Cancer Institute since 2011. He is now a David Cole Family Endowed Professor, a Georgia Research Alliance Distinguished Cancer Scientist and Halpern Research Scholar. He has served as Co-Director of Thoracic Cancer Program of Winship Cancer Institute of Emory University and is the current president of US-Chinese Anticancer Association (USCACA). Dr. Sun's current research has primarily focuses on understanding and managing acquired resistance to third generation EGFR inhibitors as well as to RAS-targeted therapy. Dr. Sun has been on the editorial boards of over 30 cancer-related

journals and reviewed manuscripts for over 100 scientific journals. He has been actively engaged in evaluating or reviewing grants for over 10 international organizations including different USA NIH/NCI study sections such as Cell Signaling Regulatory System (CSRS) study section (2021-2025). He has published over 170 original research papers in prominent peer-reviewed journals since 1994 in addition to over 30 reviews, editorials or commentary articles. He has supervised over 30 postdoctoral fellows and 20 visiting students and scholars.

Wei Xu, Ph.D., *ACACR President-elect.* Dr. Xu received a B.S. in Chemistry from Beijing University and an M.S. in Biophysics from the Institute of Biophysics, Chinese Academy of Sciences. She received a Ph.D. in Biochemistry from Univ. of Iowa. After postdoctoral training with Dr. Ronald Evans in the Salk Institute, she started as a tenure-tracked assistant professor at Univ. of Wisconsin-Madison in 2005. She was promoted from Assistant Professor to Full Professor in 9 years. The Xu lab focuses on targeting estrogen receptors and epigenetic regulators for breast cancer therapy. Dr. Xu's laboratory has employed biochemical and functional genomic approaches, as well as mouse genetics, to decipher the contribution of protein arginine methylation to the epigenetic control of cancer cells. Dr. Xu revealed essential roles of "writers" and "readers" of protein arginine methylation in breast carcinogenesis and genetic drivers for the development of Wilms tumors. Dr. Xu is a Marian A. Messerschmidt Professor in Cancer Research and Vice Chair in the Department of Oncology. Dr. Xu is also the PI for Cancer Biology T32 training grant and the Genetics and Epigenetics Program co-leader for Carbone Comprehensive Cancer Center, Univ. of Wisconsin-Madison. Dr. Xu has received numerous awards, including the Department of Defense Era of Hope Scholar Award, the Society of Toxicology Achievement Award, the AACR-Bayer Innovation and Discovery Grant, AAAS fellow, among others.

.

Shi-Yuan Cheng, Ph.D. Dr. Cheng is currently a tenured Professor of Neurology at The Ken & Ruth Davee Department of Neurology, Lou & Jean Malnati Brain Tumor Institute, and the Lurie H. Robert Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL USA. Dr. Cheng was the President of US Chinese Anti-Cancer Association (USCACA) in 2013-2017, a non-profit professional organization that facilitates collaborations among cancer researchers and physicians in US and China. Dr. Cheng was also the funding president of Association of Chinese American in Cancer Research (ACACR). Dr. Cheng received his B.S. degree in biochemistry from Wuhan University in Wuhan, China in

1982 and his Ph.D. degree in biochemistry from The Ohio State University in Columbus, Ohio, USA in 1992. From 1992 to 1999, Dr. Cheng received his postdoctoral trainings at UCSD and the Ludwig Institute for Cancer Research in La Jolla, California, USA. From 1999 to 2012, Dr. Cheng was appointed as an Assistant then a tenured Associate Professor at Hillman Cancer Center & Department of Pathology at University of Pittsburgh School of Medicine, Pittsburgh, PA. In 2012, Dr. Cheng joined faculty at Northwestern University as a tenured Professor at the Department of Neurology. Dr. Cheng is a fellow of American Association for the Advancement of Science (AAAS). He was also honored as a Zell Scholar, Kimmel Scholar, and V Scholar for Cancer Research. Dr. Cheng is an associate editor at Genes & Diseases, and an editorial board member of Neuro-Oncology, Journal of Biological Chemistry, Journal of Neuro-oncology. Dr. Cheng has published over 100 peer-reviewed research articles in top-ranking biomedical journals as first, senior or co-author including *Cancer Cell*, *Nat Cell Biol*., *Mol. Cell, JCI*, *Nat Commoms, PNAS*, *Cell Reports, Cancer Res.* and >20 invited review articles, editorials, and book chapters. Dr. Cheng's research interests are to study dysregulated oncogenic signaling, non-coding RNAs, autophagy, epigenetics, and ferroptosis in adult and pediatric brain gliomas, RNA splicing in glioma tumor and tumor-associated myeloid cells and T cells, mechanisms underlying GBM resistance to TMZ, and develop novel therapeutic approaches for treating brain tumors. His research has been continuously supported by the US NIH, American Cancer Society, DOD Research Programs, and other funding agencies.



Wenwei Hu, Ph.D. Dr. Hu is a professor in the Department of Radiation Oncology at Rutgers Cancer Institute, Rutgers University. Dr. Hu received both her M.B. and Ph.D. degrees in cancer biology from Zhejiang University School of Medicine. She then received postdoctoral training at NYU Medical School, focusing on DNA damage and repair, before she moved to the University of Medicine and Dentistry of New Jersey continuing her postdoctoral training with Dr. Arnold Levine studying p53 and its signaling pathway. Since 2009, Dr. Hu has been a faculty member at Rutgers Cancer Institute of New Jersey. The major research interests of Dr. Hu's group include the study on the function and regulation of p53 in both wild-type and mutant forms, which in turn impacts tumorigenesis; and the role of LIF, a cytokine that is a p53 target, in tumorigenesis and other human diseases. Dr. Hu has authored or co-authored over 100 peer-reviewed publications. She has received many awards, including ACS Research Scholar, Ellison Medical Foundation Young Investigator Award, DOD New Investigator Award for Genetic Cancer Research, AACR-ITO EN Young Investigator Award, and Rutgers University Board of Trustees Research Fellowship for Scholarly Excellence, among others. Her research has been continuously supported by NIH/NCI, DoD, American Cancer Society, Ellison Medical Foundation, and other funding agencies.

Zhenkun Lou, *Ph.D.* Dr. Lou is the Swanson/Schmucker Endowed Professor of Cancer Research, Professor of Pharmacology, Chair of the Division of Oncology Research, and Co-Leader of the Cell Genomics, Signaling, and Metastasis Program at the Mayo Clinic. His research focuses on signaling pathways activated by DNA damage-inducing radiation and chemotherapy. For over two decades, Dr. Lou's laboratory has been at the forefront of DNA repair pathway research, making significant contributions to the field. His team was among the first to characterize key players in the DNA damage response (DDR) pathway, shedding light on how factors such as ATM, ATR, DNA-PK, MDC1, NBS1, 53BP1, BRCA1, and Rad51 are activated or assembled at sites of DNA damage. Their studies have been instrumental in understanding how these factors facilitate DNA repair through non-homologous end joining (NHEJ) and homologous recombination (HR). Additionally, his lab was the first to characterize multiple E3 ligases and deubiquitinases involved in the DDR pathway. Beyond fundamental research, Dr. Lou's lab conducts extensive translational studies to explore how cancer cells respond to radiation, PARP inhibitors, and other DNA damage-inducing chemotherapies, as well as the mechanisms of resistance. Dr. Lou has published over 130 peer-reviewed papers, many in high-impact journals including *Nature, Cell, Cancer Cell, Cancer Discovery, Nature Cell Biology, Nature Cancer,* and *Molecular Cell*. His contributions have earned him numerous accolades, including the Richard Schulze Scholar Research Award, recognition as a Susan G. Komen Scholar, and election as an AAAS Fellow. He also served as the ACACR President from 2018 to 2020.

Erxi Wu, Ph.D., ACACR General Secretary. Dr. Wu is a dedicated cancer biologist and neuroscientist, whose work has gained both national and international acclaim. He is Professor at Baylor College of Medicine (BCM), Vice Chair for Research in the Department of Neurosurgery at BCM-Temple, Deputy Director of Neuroscience Institute at Baylor Scott & White Health (BSWH), and Chief, Neuro-Oncology Research, Neuroscience Institute at BSWH as well as Clinical Professor at Texas A&M School of Medicine; he is Professor (Affiliate) of the Cancer Research Center and Department of Internal Medicine, Dell Medical School at the University of Texas at Austin (UT Austin). Critically, Dr. Wu is the PI and Director of the CPRIT Cancer Agent Target Discovery and Aptamer Development (CATDAD) Core at BSWH. Central to his research program is the development of biomarkers, the identification of therapeutic targets, and the discovery of novel drugs for cancer and neurodegenerative diseases. Among his notable achievements are the discovery of agents targeting cancer stem cells, the establishment of a comprehensive biomarker analysis platform, and significant advancements in understanding neurodegenerative disease pathology. Dr. Wu obtained Ph.D. from the University of Sheffield, UK under the tutelage of Professor Graham Russell and received

postdoctoral training with Professor Margaret Shipp at Dana-Faber Cancer Institute, Harvard University. He has published 196 scientific papers in various scientific journals, many of which are highly regarded, such as *Signal Transduction and Targeted Therapy, Nature Medicine, Nature Methods, Molecular Cancer, Bioactive Materials, Journal of the American Chemical Society*, *Nature Communications, Journal of Clinical Investigation, Brain, Molecular Therapy,* and *Science Advances* resulting in over 10,700 citations and an H-index of 58. Supported by grants from the NIH, CPRIT, and others, his work extends to the scientific community through roles like NIH study section reviewer since 2017 and editorial positions with *Genes & Diseases* and *Drug Resistance Updates*. He has reviewed for over 150 scientific journals, delivered over 40 seminars globally, and introduced Nobel Laureates at conferences. Mentorship is a key aspect of his career, guiding over 80 professionals in their academic and industry endeavors. His involvement in shaping educational curricula and leadership roles in organizations like ACACR (President-Elect 2026-2028) reflects his commitment to advancing science. Dr. Wu serves as the President of the Chinese Association for Science & Technology USA (CAST-USA) (2025-2026). Dedicated to pioneering new diagnostic and therapeutic methods for cancer and neurodegenerative diseases, he strives to impact human health through teaching, research, service, and leadership.

Dr. Lin Zhang, Ph.D. Dr. Zhang is a Professor of Medicine at the Norris Comprehensive Cancer Center, Keck School of Medicine of University of Southern California (USC). He received his BS in Biochemistry from Sichuan University, and PhD in Molecular Biology from USC. After postdoctoral training at Johns Hopkins with Dr. Bert Vogelstein, he started his faculty position in 2002 at the University of Pittsburgh Hillman Cancer Center. He returned to USC in 2023 as a tenured Professor at the Department of Medicine. Dr. Zhang has tried to gain deep understanding on how cell death is initiated and executed in response to stress and drug treatment in colorectal cancer cells; how oncogenic driver mutations affect cell death signaling and ensuing antitumor immunity; why most of colorectal tumors respond poorly to therapeutic treatment; and what can be done to stimulate tumor cell killing and restore immunosurveillance of cancer. His long-term goal is to translate basic research findings on cell death to novel strategies and agents for improving colorectal cancer treatment and prevention. Dr. Zhang has authored over 150 research and review articles. His research has been continuously supported by NCI and led to multiple NCI-sponsored clinical trials. He received several honors including V Scholar, General Motor Scholar, ACS Research Scholar, and American Lung Association Career Investigator Award. He has served in NIH study sections and editorial boards of Cancer Research and other journals. He was a member of the AACR Special Conferences and Annual Meeting Program Committees. He was also a founding member of ACACR and served as the ACACR President from 2021 to 2022.

Dr. Jing Yang, Ph.D. Dr. Yang, an esteemed Professor of Pharmacology at the University of California, San Diego, is a prominent figure in the field of oncological research. Her academic journey includes a Ph.D. from Duke University, followed by a postdoctoral fellowship at the Whitehead Institute. Professor Yang's expertise primarily lies in the realm of tumor metastasis, delving into areas such as the Twist gene, invadopodia, the degradation of the extracellular matrix, mechanobiology, and the intricacies of matrix stiffness. A significant portion of her work is dedicated to unraveling the complexities of the Epithelial-Mesenchymal Transition (EMT) process and its implications in cancer metastasis. The Yang Laboratory stands out for its cutting-edge use of functional genomics along with advanced cellular and molecular biology techniques. Her current research initiatives are groundbreaking, encompassing the dissection of the mechanotransduction pathway in breast cancer, investigating the regulatory mechanisms of metastasis dormancy, deciphering the role of invadopodia in cancer progression, and examining how epithelial polarity influences EMT and metastatic processes. Dr. Yang's contributions to the field are evidenced by her high-quality publications in esteemed journals such as Cell and Cancer Cell, showcasing her dedication to advancing our understanding of cancer biology. Her work not only enhances academic knowledge but also holds significant potential for developing novel therapeutic strategies in the battle against cancer.



Lanjing Zhang, M.D., ACACR Treasurer. Dr. Zhang is the Chair of the Department of Pathology and Laboratory Medicine, Princeton Medical Center, Plainsboro, NJ. He is also a Research Professor of Chemical Biology at Rutgers Ernest Mario School of Pharmacy, Piscataway, NJ, a Full Member of Rutgers Cancer Institute of New Jersey. His research focuses on epidemiology, machine learning, computational biology, hepatology and cancer. Dr Zhang has published more than 130 articles and letters. He has mentored more than 10 undergraduate and graduate students, and is funded by the NSF and NIH, USA. His honors include the Ramzi Cotan Award from the US and Canadian Academy of Pathology, the Presidential Award from Sonic Healthcare USA and the MERIT (R37) Award from the NCI, NIH. He served on a panel of the Medical Devices Advisory Committee, U.S. FDA, regularly reviews grant proposals for U.S. and foreign governmental agencies, presided the New Jersey Society of Pathology (2019-2021) and chaired the steering committee of Cancer Epidemiology Service, New Jersey State Department of Health. Dr Zhang is on the editorial boards of several peer-reviewed biomedical journals. He was the editor of the ACACR newsletter in 2022-2023 and has been the Treasurer of the ACACR since 2023.



Qing Zhang, Ph. D. Dr. Zhang obtained his Bachelor's degree from Wuhan University in China in 2001 followed by a Ph.D study working with Dr. Jennifer Grandis at Department of Pharmacology, University of Pittsburgh School of Medicine until Late 2005. From 2006 to early 2013, He worked as a postdoctoral fellow (2006-06/2011) and an instructor (07/2011-01/2013) in the lab of Nobel Laureate Dr. William Kaelin Jr. at Dana Farber Cancer Institute on prolyl hydroxylase and oxygen sensing pathway in cancer. He became an assistant professor at Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill in Feb of 2013. He was promoted to associate professor with tenure in Feb of 2019 at UNC Chapel Hill and now he is a tenured full professor with tenure in the Department of Pathology at UT Southwestern Medical Center (UTSW) in Dallas. He also serves as the Director of Investigative Pathology at UTSW. He is endowed with Komen Distinguished Chair at UTSW. He is also currently holding the title of Cancer Prevention & Research Institute of Texas (CPRIT) Scholar in Cancer Research. Dr. Zhang has made a number of discoveries to deepen our understanding of oxygen sensing signaling pathway in cancer. These discoveries include identifying new regulatory pathways regulated by tumor suppressor Von Hippel Lindau (VHL) in kidney cancer and potential new therapeutic targets in oxygen sensing signaling in breast cancer. For his work, Dr. Zhang has received numerous honors, including the Kimmel Scholar (2014), Susan G. Komen Career Catalyst Award (2014), the V Scholar (2015), Mary Kay Foundation Award (2017), American Cancer Society Research Scholar Award (2018), CPRIT Rising Star Award (2019), Outstanding Investigator Award from American Society for Investigative Pathology (ASIP) and Young Investigator Award from Chinese Biomedical Investigator Society (CBIS).

Dr. Xiaoqi Liu, *Ph. D.* Dr. Liu is the current Chair and Professor of Department of Toxicology and Cancer Biology, Lucille P. Markey Endowed Chair in Oncology Research, Markey Cancer Center at University of Kentucky. Dr. Liu has a broad background in cancer biology, with specific training and expertise in signaling transduction, cell cycle regulation, DNA damage repair, and therapy resistance in the context of prostate cancer and lung cancer. Dr. Liu received his BS in chemistry at Peking University in 1991, and MS in Institute of Biophysics at Chinese Academy of Science in 1994. Dr. Liu received his PhD at Washington State University in 1999 by working on DNA repair of UV-induced DNA damage. Dr. Liu did his post-doctoral training at Harvard University by working on signal transduction in mitosis, particular polo-like kinase 1 (Plk1). Dr. Liu started his independent laboratory at Purdue University in 2006 by focusing on understanding the regulation of Plk1 in cancer cells. Dr. Liu has published 130 peer-reviewed research articles so far. Dr. Liu's research program has been well funded by

various agencies including NSF, ACS, DoD, and NIH. In short, Dr. Liu has established his reputation as one of major contributors of the Plk1 field over the last 20 years. In 2018, Dr. Liu was recruited to University of Kentucky as Chair of Department of Toxicology and Cancer Biology.

Gold Sponsors

Massachusetts Biological Instruments Co.(MBI)

Biofuraw®

Founded in 2015 in Boston, Massachusetts Biological Instruments Co.(MBI) focuses on the development, production and sales of nucleic acid and protein electrophoresis products, Gel Doc and Chemi Doc. Through technical cooperation and supply chain cooperation with many places around the world, MBI has innovated and iterated products in the existing market, improved the experimental effect of related products, and provided more cost-effective related products.

MedChemExpress (MCE)

MCE® MedChemExpress

MCE offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.

https://www.medchemexpress.com/about-us.htm

Metware Biotechnology Inc

Innovative Metabolomics Insights for Better Health

Metware Biotechnology Inc (MetwareBio) is a proteomics and metabolomics service company focusing on developing and applying innovative LC-MS based multi-omics technologies to life science and health research. Since its establishment, MetwareBio has constructed an ever-increasing curated database of metabolites and a proprietary detection methodology. The database now houses over 280,000 compounds with 30,000 plant metabolites and 3,000 mammalian standard verified metabolites. MetwareBio offers the following key services:

- Global Metabolomics and Lipidomics profiling
- Global Proteomics profiling in blood, tissue, and cells.
- Targeted metabolomics in key metabolomics pathways including energy metabolism, tryptophan metabolism, amino acids, and bile acids.

MetwareBio is committed to providing effective and timely metabolomics services for basic and clinical research worldwide. Contact us as www.metwarebio.com.

TargetMol

A DRUG SCREENING EXPERT

TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 50+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds. https://www.targetmol.com/about-us

RayBiotech

RayBiotech was founded in 2001 and has grown from its humble origins to a company with over 150 employees and a 35,000 sq ft facility in Peachtree Corners, Georgia with GMP, GLP and ISO 13485 certifications. RayBiotech's mission is to provide cutting-edge array technologies that accelerate the discovery of disease-related protein biomarkers and key factors, the identification of new drug targets, and the advancement of personalized medicine.

https://www.raybiotech.com/about-us

KYINNO

KYinno is a preclinical contract research organization (CRO) providing customized services of in vitro and in vivo pharmacology, cell line engineering, therapeutic target identification, and antibody discovery powered by its unique proprietary assets of 3000+ engineered cell lines, bispecific and tri-specific antibody discovery mouse models, 5000-antibody specificity screening MPSA-AB5000 panel, and the KY-AI™ antibody development artificial intelligence platform.

https://www.kyinno.com/

RWD Life Science Co., Ltd.

Established in 2002 and headquartered in Shenzhen, with a branch in the USA, RWD Life Science is a national high-tech enterprise specializing in the life science, animal health, and clinical medical fields.

We commit to contributing wisdom and strength to enhancing life quality, building an enabling platform that integrates research, education, application, and industrialization.

Through sustained investment in R&D innovation, we have established seven core solutions: animal surgery and modeling, animal neural signal research, microcirculation detection and in vivo imaging, cellular and molecular biology research, animal behavioral research, animal diagnostics and treatment, and histopathological sectioning protocol. These integrated systems meet specialized equipment requirements across diverse scientific fields.
https://www.rwdstco.com/

ACACR acknowledges the BioInfoRx Inc. for creating and maintaining ACACR.org website

BioInfoRx: Achieve More with LESS

BioInfoRx provides Laboratory Essential Software Solutions (LESS) for scientific research, covering lab management, data analysis, and custom system needs.

Learn More at https://bioinforx.com/

BioInfoRx: Cloud Solutions for Research Labs

BioInfoRx delivers specialized SaaS solutions for academic institutions, non-profits, research labs, and biotech companies. Their cloud-based platforms streamline laboratory information management and biological data analysis through advanced bioinformatics.
Addressing the primary challenge of information management in research environments, BioInfoRx eliminates the need for in-house IT infrastructure, allowing scientists to focus on research rather than technology maintenance.
Their proprietary BioInfoRx Application Framework (BxAF) enables flexible, secure, and regulatory-compliant information systems that can be implemented across various programming languages and databases. This market-proven technology has been validated by thousands of researchers, establishing BioInfoRx as a trusted provider of integrated, cost-effective cloud solutions for the evolving needs of modern research laboratories.